Tao Lu

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research, Institute of Hematology & Blood Diseases Hospital · ORCID：0000-0001-9628-2636

发表论文 99 篇 · 总被引 989 次 · h-index 14

代表论文

Dihydroartemisinin, a potential PTGS1 inhibitor, potentiated cisplatin-induced cell death in non-small cell lung cancer through activating ROS-mediated multiple signaling pathways (2024 · Neoplasia · 被引 25)
T2WI-based MRI radiomics for the prediction of preoperative extranodal extension and prognosis in resectable rectal cancer (2024 · Insights into Imaging · 被引 19)
MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies (2025 · Journal of Medicinal Chemistry · 被引 14)
Structure-Guided Optimization of 2-Aminoquinazoline Hematopoietic Progenitor Kinase 1 Inhibitors for Improved Oral Bioavailability and Synergistic Antitumor Immunity (2025 · Journal of Medicinal Chemistry · 被引 11)
Diffusion-derived vessel density (DDVD) computed from a simple diffusion MRI protocol as a biomarker of placental blood circulation in patients with placenta accreta spectrum disorders: A proof-of-concept study (2024 · Magnetic Resonance Imaging · 被引 11)
Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy (2024 · Journal of Medicinal Chemistry · 被引 7)